Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06616766 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
A Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer), sponsored by Yuhan Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 161
- Enrollment target
- 8
- Study locations
NCT06616766 is a Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer) that is actively recruiting participants, run by Yuhan Corporation. The registered enrollment target is 161 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (27% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT06616766, a Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer), is actively recruiting participants, sponsored by Yuhan Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 161 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
Conditions Studied
Interventions
- DRUG YH42946
Study Locations (8)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University - Seoul
- Samsung Medical Center - Seoul
- Asan Medical Center, University of Ulsan - Seoul
Gyeonggi-do
- Seoul National University Bundang Hospital - Seongnam-si
- The Catholic Univ. of Korea St. Vincent's Hospital - Suwon
Virginia
- Next Oncology Virginia - Fairfax
North Chungcheong
- Chungbuk National University Hospital - Cheongju-si
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2028-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06616766
The ClinicalTrials.gov registry entry for NCT06616766 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (27% lower). The listed sponsor is Yuhan Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YH42946 is the first listed.
NCT06616766 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Gyeonggi-do, Virginia.
Frequently Asked Questions
What is clinical trial NCT06616766 about?
NCT06616766 is a clinical study titled "A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946". The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
What is the current status of trial NCT06616766?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2024-10-02. Estimated completion is 2028-07-29.
What conditions does trial NCT06616766 study?
This clinical trial studies the following conditions: Solid Tumor, NSCLC (Non-small Cell Lung Cancer).
What interventions are being tested in trial NCT06616766?
The interventions under investigation include: YH42946 (DRUG).
Who is sponsoring clinical trial NCT06616766?
This trial is sponsored by Yuhan Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06616766 being conducted?
This trial has 8 study locations across Virginia, Gyeonggi-do, North Chungcheong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.